Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Monoclonal antibody JST-010 · 1 trial · 1 indication
1. Incidence of solicited local (injection site) and systemic AEs post-injection through Day 7 (with the inpatient and outpatient participant diaries being collected on Day 3 and Day 8, respectively). 2. Incidence of unsolicited AEs through end of study (EOS). 3. Incidence of SAEs, medically attended AEs (MAAEs), and AEs of special interest (AESIs) post-injection through EOS.
| Arm | Type | Description |
|---|---|---|
| JST-010: The active investigational product | ACTIVE_COMPARATOR | - |
| JST-012 Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Monoclonal antibody JST-010 | BIOLOGICAL | Active study drug |
| Placebo | DRUG | Placebo |
Inclusion Criteria: 1. Healthy men or women 18 to 55 years of age 2. BMI between 18 and 32 kg/m2 3. Negative serum pregnancy test 4. Use of highly effective birth control method(s) for a minimum of 60 days prior to consent and is willing to continue use for at least 12 months, or abstinence 5. In g...
JST-010 is an investigational monoclonal antibody being studied as pre-exposure prophylaxis against pneumonic plague in healthy adults. It is currently in Phase 1 clinical development and has not been approved by the FDA.
JST-010 is being developed by Evotec SE, a biopharmaceutical company listed on the stock exchange under the ticker EVO. The company is conducting a Phase 1 clinical trial to evaluate the drug's safety and pharmacokinetics.
JST-010 is in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is assessing its safety and pharmacokinetics in healthy adults.
JST-010 is being studied in a Phase 1 clinical trial with the identifier NCT06943378. This is a randomized, double-blind, placebo-controlled study involving dose escalation and expansion to assess the safety and pharmacokinetics of JST-010 in healthy adults in the United States.
JST-010 is a monoclonal antibody, a type of protein designed to bind to a specific target in the body. However, the specific molecular target of JST-010 has not been disclosed in available information.